Pure Red Cell Aplasia Due to Parvovirus B19 Infection in a Man With HIV Infection

Ja, de Mayolo; Jd, Temple

doi:10.1097/00007611-199012000-00028

Cited by 21 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Parvovirusassociated PRCA, which is supposed to be a frequent cause of anemia in patients with AIDS, was ruled out. [4] There was no evidence of autoimmune hemolysis, which was supported by a negative Coombs test. In our patient, at the time of diagnosis of PRCA, the patient was receiving Zidovudine and Lamivudine.…”

Section: Discussionmentioning

confidence: 92%

Zidovudine-induced reversible pure red cell aplasia

et al. 2010

View full text Add to dashboard Cite

Hematological abnormalities are frequent among human immunodeficiency virus (HIV)-infected patients and may be directly attributable to the virus or may be caused by opportunistic infections, neoplasms or drugs that cause bone marrow suppression or hemolysis. Pure red cell aplasia (PRCA) is an uncommon hematological disorder that causes anemia. We report a 37-year-old male with HIV infection who developed PRCA 6 weeks after commencing Zidovudine and recovered following cessation of the drug. This is the first case of Zidovudine-induced PRCA reported from the Indian subcontinent.

show abstract

Section: Discussionmentioning

confidence: 92%

Zidovudine-induced reversible pure red cell aplasia

et al. 2010

View full text Add to dashboard Cite

show abstract

“…[1]. There are only a few AIDS-associated PRCA cases reported [8][9][10]. The most accepted mechanisms for AIDSassociated PRCA are an autoimmune response as a consequence of the immune-dysregulated status of AIDS (immunity initially directed against infectious agents), and the myelosuppressive effect of the antiretroviral therapy.…”

Section: Discussionmentioning

confidence: 99%

Lamivudine-induced pure red cell aplasia

et al. 2000

View full text Add to dashboard Cite

The aim of this report is to describe five patients with lamivudine-induced pure red cell aplasia, an association not previously described. We describe patients with unresponsive anemia in whom a complete study including blood cell counts, reticulocyte counts, hemolysis tests, and bone marrow aspiration was performed. Pure red cell aplasia was considered when anemia was associated with normal leukocyte and platelet counts with a corrected reticulocyte count below 1% and less than 5% bone marrow erythroid progenitors in the absence of positive hemolysis tests. Complete remission was considered when bone marrow erythroid progenitors were at least 16%. Five male patients had pure red cell aplasia with a median age of 32 years (range 29 to 37 years). Before lamivudine, they had hemoglobin >11.8 g/dl without transfusion requirements. After receiving the drug, hemoglobin dropped to 5.2 g/dl (4.3 to 6.1 g/dl) with high transfusion requirements and mean bone marrow erythroid progenitors of 1.84% (0 to 4%). Withdrawal of lamivudine was attempted to confirm the diagnosis. Seven weeks after stopping lamivudine, hemoglobin rose up to 12.8 g/dl (11 .3 to 13.8 g/dl) and bone marrow erythroid progenitors increased up to 25.6% (21 to 40%) without transfusion requirements. Lamivudine-induced pure red cell aplasia may be a cause of anemia unresponsive to conventional treatment in AIDS. Since lamivudine use in Mexico has been relatively short, we expect more cases to appear in the future.

show abstract

“…Chemotherapy-related impaired immune response and reduced bone marrow compensatory capacity may have prolonged the bone marrow-cell infection in our patients. Persistent B19 infection has also been reported in other patients with various conditions, such as proven or suspected congenital immunodeficiency syndromes [6,7,25,26], acquired immunodeficiency syndrome (AIDS) [8,[27][28][29][30][31], following allogenic bone marrow transplantation [32,33], and in B19 arthropathy [34]. The persistent B19 bone marrow infection in immunocompromised patients, which can also be seen in patients with normal B19 IgG levels, is probably associated with failure to produce neutralizing antibodies and/or a deficient T-cell response [35].…”

Section: Discussionmentioning

confidence: 98%

Persistent B19 parvovirus infection in pediatric malignancies

Broliden

Tolfvenstam

Ohlsson

et al. 1998

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Background and Procedure The frequency and clinical importance of parvovirus B19 infection were studied in children investigated or treated for various malignancies and cytopenias. Results. B19 infection was thus demonstrated in six out of 53 unselected children with malignancies by bone marrow examination, using the B19, DNA‐specific, polymerase chain reaction (PCR). Examinations using the PCR in serum samples were equally or less sensitive than in bone marrow samples. One of the children had a persistent B19 infection during maintenance therapy for acute lymphoblastic leukemia. She developed a prolonged and severe cytopenia, and the clinical signs included facial rash, chills, high undulating fever, and pharyngitis. She also seroconverted and became B19 IgM‐antibody positive during the study period. Conclusions. Parvovirus B19 infection was detected in 10% of the children and was either asymptomatic or was associated with severe and prolonged cytopenia. Bone marrow examinations are recommended for the detection of B19 DNA in immunosuppressed children. Med. Pediatr. Oncol. 31:66–72, 1998. © 1998 Wiley‐Liss, Inc.

show abstract

Pure Red Cell Aplasia Due to Parvovirus B19 Infection in a Man With HIV Infection

Cited by 21 publications

References 0 publications

Zidovudine-induced reversible pure red cell aplasia

Zidovudine-induced reversible pure red cell aplasia

Lamivudine-induced pure red cell aplasia

Persistent B19 parvovirus infection in pediatric malignancies

Contact Info

Product

Resources

About